🇺🇸 FDA
Pipeline program

AGAMREE 40 mg/ml oral suspension

SNT-IV-VAM-011

Approved small_molecule active

Quick answer

AGAMREE 40 mg/ml oral suspension for Duchenne Muscular Dystrophy is a Approved program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Duchenne Muscular Dystrophy
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials